List of Rykindo drug patents
Rykindo is owned by Shandong Luye.
Rykindo contains Risperidone.
Rykindo has a total of 5 drug patents out of which 0 drug patents have expired.
Rykindo was authorised for market use on 13 January, 2023.
Rykindo is available in for suspension, extended release;intramuscular dosage forms.
Rykindo can be used as treatment of schizophrenia in adults.
The generics of Rykindo are possible to be released after 10 April, 2032.
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10406161 | SHANDONG LUYE | Risperidone sustained release microsphere composition |
Apr, 2032
(8 years from now) | |
| US10098882 | SHANDONG LUYE | Risperidone sustained release microsphere composition |
Apr, 2032
(8 years from now) | |
| US9532991 | SHANDONG LUYE | Risperidone sustained release microsphere composition |
Apr, 2032
(8 years from now) | |
| US9446135 | SHANDONG LUYE | Risperidone sustained release microsphere composition |
Apr, 2032
(8 years from now) | |
| US11110094 | SHANDONG LUYE | Risperidone sustained release microsphere composition |
Apr, 2032
(8 years from now) | |
Drugs and Companies using RISPERIDONE ingredient
Market Authorisation Date: 13 January, 2023
Treatment: Treatment of schizophrenia in adults
Dosage: FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic